Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
Author
Source
Dermatology Research and Practice
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-11-02
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Psoriasis is a common, chronic, immune mediated, inflammatory disease of skin characterized by red patches enclosed with white scales and affects 2-3% of people in the world.
Topical therapy, phototherapy, and systemic therapy were employed for management of disease from many last decades.
However, long term uses of these agents are associated with unwanted effects and toxicities.
Recently, Itolizumab has been developed as world’s first anti-CD6 humanized monoclonal IgG1 antibody for the management of moderate-to-severe chronic plaque psoriasis in India.
Here we are presenting the response indicated by Itolizumab in 7 Indian patients having moderate-to-severe psoriasis with severe comorbidities and who were intolerant/nonresponding to conventional therapies.
American Psychological Association (APA)
Singh, Vinay. 2016. Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions. Dermatology Research and Practice،Vol. 2016, no. 2016, pp.1-4.
https://search.emarefa.net/detail/BIM-1103831
Modern Language Association (MLA)
Singh, Vinay. Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions. Dermatology Research and Practice No. 2016 (2016), pp.1-4.
https://search.emarefa.net/detail/BIM-1103831
American Medical Association (AMA)
Singh, Vinay. Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions. Dermatology Research and Practice. 2016. Vol. 2016, no. 2016, pp.1-4.
https://search.emarefa.net/detail/BIM-1103831
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1103831